03320.HK
China Resources Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 4.35
+1.75%Sep 18, 2026, 04:30 UTC
China Resources Pharmaceutical Group's subsidiary China Resources Pharmaceutical Commercial signed a strategic cooperation agreement with Sino Biopharmaceutical covering drug commercialization and distribution, supply chain coordination, drug development, market access, DTP pharmacies and patient disease management, targeting a cooperation scale of RMB 10 billion.
Source:Sep 11, 2026, 04:16 UTC
China Resources Pharmaceutical's subsidiary China Resources Sanjiu received approval from the National Medical Products Administration to launch mupirocin ointment in mainland China.
Source:Aug 24, 2026, 13:00 UTC
China Resources Pharmaceutical Group Limited advanced its innovative drug pipeline, with a Class 1 antidepressant entering Phase IIb, DC6001 receiving clinical trial approvals in China and the U.S. and FDA Pediatric Rare Disease Designation, and DC7001A filed in China and the U.S.
Source:Aug 24, 2026, 08:47 UTC
China Resources Pharmaceutical reported interim results for the six months ended June 2026, with net profit up 5.3% to RMB 2.187 billion and total revenue up nearly 2% to RMB 134.458 billion.
Aug 24, 2026, 08:33 UTC
China Resources Pharmaceutical Group announced an interim dividend of RMB 0.087 per share.
Aug 12, 2026, 07:23 UTC
Hangzhou Bailun Testing Technology, a wholly-owned subsidiary of Baicheng Pharmaceutical, won a procurement contract from Kunming Pharmaceutical Group for gene toxicity impurity assessment services.
Source:Aug 3, 2026, 04:21 UTC
China Resources Pharmaceutical's subsidiary China Resources Jiangzhong Pharmaceutical obtained regulatory approval from China's State Administration for Market Regulation for two new special medical foods, expanding its portfolio to four registered products.
Source:Jul 29, 2026, 13:07 UTC
China Resources Pharmaceutical Group issued the second tranche of 2026 medium-term notes with a principal amount of 1 billion yuan, a three-year term, and an annual coupon rate of 1.52%.
Source:Jul 23, 2026, 01:23 UTC
China Resources Pharmaceutical Group's wholly-owned subsidiary China Resources Pharmaceutical Holdings completed the issuance of 1 billion yuan in medium-term notes with a coupon rate of 1.53%.
Source: